Test Price
2,800 AED✅ Home Collection Available
COL6A1 Gene Sequencing for Ullrich Congenital Muscular Dystrophy (Genetic Test)
Executive Summary & Core Metrics
This NGS‑based genetic test detects pathogenic variants in the COL6A1 gene, confirming Ullrich Congenital Muscular Dystrophy (UCMD) with 99.9% diagnostic sensitivity under ISO‑certified processing and DHA‑compliant protocols. The analysis covers all coding regions, exon‑intron boundaries, and copy‑number variants for comprehensive molecular diagnosis.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection, available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post‑Test Genetic Counselling for result interpretation and family planning.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This comprehensive next‑generation sequencing test analyzes the entire COL6A1 gene for mutations causing Ullrich Congenital Muscular Dystrophy, a severe early‑onset neuromuscular disorder characterised by muscle weakness, joint contractures, and respiratory complications. The test provides a definitive molecular diagnosis to guide clinical management, prognosis, and family counselling.
| Feature | Our Test (NGS Panel) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene sequencing + deletion/duplication analysis; detects >99% of pathogenic variants | Sequential exon‑by‑exon analysis; may miss large rearrangements |
| Methodology | Next Generation Sequencing (NGS) with bioinformatic pipeline | Traditional Sanger sequencing, limited throughput |
| Turnaround Time | 3–4 Weeks | 6–10 Weeks |
| Certification | ISO 9001:2015 (INT/EGQ/2509DA/3139) & DHA Compliant | May lack UAE‑specific accreditation |
Physician Insight & Safety Protocols
“When a child presents with progressive muscle weakness, delayed motor milestones, and joint stiffness, families carry an immense emotional burden searching for answers. This COL6A1 gene test provides a precise molecular confirmation of Ullrich Congenital Muscular Dystrophy, enabling targeted care, anticipatory respiratory management, and informed reproductive choices. However, genetic results must always be interpreted alongside a thorough clinical examination by a specialist—never in isolation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Treatment Advisory
Important Safety Notice
Do not discontinue, adjust, or initiate any prescribed therapy—including corticosteroids, respiratory support, or cardiac medications—based solely on genetic test results. Always consult your treating physician for personalised medical advice.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: Inability to provide a blood or DNA sample (e.g., severe coagulopathy); lack of clinical suspicion of congenital muscular dystrophy confirmed by a specialist; active respiratory infection that may compromise safe sample collection.
ER Red Flags: New‑onset respiratory distress, rapid decline in feeding ability, or signs of cardiac compromise (arrhythmia, syncope, chest pain) warrant immediate emergency evaluation regardless of test results.
Patient FAQ & Clinical Guidance
1. What is the COL6A1 gene test for Ullrich congenital muscular dystrophy?
This NGS test sequences the full COL6A1 gene to detect mutations responsible for Ullrich Congenital Muscular Dystrophy, a severe early‑onset neuromuscular condition. It provides a molecular diagnosis that confirms clinical suspicion and guides management, prognosis, and family planning. The assay examines all coding regions, exon‑intron boundaries, and copy‑number variants for comprehensive variant detection.
2. How is the test performed and what is the turnaround time?
A small blood sample or DNA swab is collected by our certified phlebotomist via home visit using hospital‑grade cold‑chain logistics, then processed through NGS with results available in 3–4 weeks. DNA is extracted, enriched, and sequenced on an Illumina platform, followed by bioinformatic analysis in accordance with DHA guidelines to ensure reliable variant interpretation.
3. Is this genetic test covered by insurance in the UAE?
We provide direct billing verification—simply WhatsApp your insurance card to +971 54 548 8731 for instant confirmation of coverage. Our team works with all major UAE insurers and can obtain pre‑approval on your behalf. Flexible self‑pay options are also available with transparent pricing at 2800 AED.
4. Can I receive genetic counselling after the test?
Yes, every test includes telephonic post‑test genetic counselling by our consultant medical geneticist. This session covers result interpretation, recurrence risks, carrier testing for family members, and coordination with your neurologist or paediatrician for ongoing care.
UAE Regulatory & Data Privacy Adherence
Your genetic data is handled under the strictest UAE privacy and security frameworks:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and storage of all personal health information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — regulating digital health records and telemedicine interactions.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — ensuring clinical safety and patient consent prior to any diagnostic procedure.
All laboratory processes adhere to DHA standards and ISO 9001:2015 certification (INT/EGQ/2509DA/3139), with encrypted data transmission and role‑based access controls to protect patient confidentiality.
Clinical & Logistical Metadata
| Test Name | COL6A1 Gene Sequencing for Ullrich Congenital Muscular Dystrophy |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Buccal Swab; VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next Generation Sequencing (NGS) with deletion/duplication analysis |
| ICD-10-CM Code | G71.0 |
| LOINC Code | 94531-1 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians